Calcinosis Cutis Dog: Comprehensive Veterinary Reference Guide

Quick Q&A

Question: What is calcinosis cutis in dogs, and is it curable?

Answer: Calcinosis cutis is a rare skin condition in dogs characterized by the deposition of calcium salts within the dermis, epidermis, and subcutaneous tissues. It is most commonly associated with hyperadrenocorticism (Cushing's disease). While the skin lesions themselves can be managed, the condition is typically a symptom of an underlying endocrine disorder; therefore, treatment focuses on resolving the primary disease, which can lead to regression of the calcinosis.

Introduction

Calcinosis cutis is a relatively uncommon but clinically significant dermatologic condition in dogs, representing a pathological process where insoluble calcium salts are deposited within the skin and subcutaneous tissues. For the veterinary professional and the concerned pet owner alike, understanding this condition is essential, as it is often a visible marker of a serious underlying systemic disease, most notably hyperadrenocorticism (Cushing's syndrome). This comprehensive guide aims to provide an exhaustive review of calcinosis cutis in dogs, covering its pathophysiology, aetiology, clinical presentation, diagnostic approach, treatment options, and prognosis. By integrating current veterinary medical knowledge with practical clinical guidance, this article serves as a definitive reference for managing this challenging condition.

The term "calcinosis cutis" is derived from the Latin calx (lime) and the Greek kutis (skin). In veterinary medicine, it is distinct from other forms of calcification, such as calcinosis circumscripta (tumoural calcinosis), which presents as discrete, nodular deposits often over bony prominences. Calcinosis cutis, by contrast, is a more diffuse, dystrophic process. The primary keyword for this guide is "calcinosis cutis dog," reflecting the high search volume and clinical relevance of this topic for pet owners and veterinarians, particularly in the United States, Canada, Europe, and Australia.

What is Calcinosis Cutis in Dogs?

Calcinosis cutis is defined as the deposition of calcium salts (primarily hydroxyapatite) within the skin. This is not a simple precipitation event; it is a complex pathological process that can be triggered by several mechanisms. In veterinary medicine, it is most frequently encountered as a dystrophic calcification, where calcium deposits form in tissues that have been previously damaged, inflamed, or necrotic. However, in dogs, the most common underlying cause is endocrine in origin.

Pathophysiology

The pathophysiology of calcinosis cutis is multifactorial. In the context of hyperadrenocorticism, the primary driver is the excess of glucocorticoids (cortisol). Glucocorticoids have a catabolic effect on collagen and other connective tissue components. They inhibit fibroblast proliferation and collagen synthesis, leading to dermal atrophy and fragility. This damaged, weakened collagen matrix becomes a nidus for calcium deposition. Furthermore, glucocorticoids can alter local calcium and phosphorus metabolism, potentially increasing the local calcium-phosphorus product, which favours precipitation. The exact mechanism remains incompletely understood, but it is clear that the presence of altered or degenerated collagen is a prerequisite.

Other proposed mechanisms include:

• Increased intracellular calcium influx: Damaged cell membranes allow calcium to enter cells, where it binds to phosphate and precipitates.
• Local tissue alkalosis: An alkaline environment favours calcium salt precipitation.
• Matrix vesicle release: Degenerating cells release matrix vesicles that can nucleate calcium crystal formation.

Histopathology

On histopathological examination, calcinosis cutis is characterized by the presence of basophilic, granular, or amorphous deposits of calcium salts within the dermis and subcutaneous tissue. These deposits are often surrounded by a foreign body reaction, including macrophages (histiocytes) and multinucleated giant cells attempting to phagocytose the mineral. The overlying epidermis may be hyperplastic, ulcerated, or necrotic. Special stains, such as von Kossa (which stains calcium phosphate black) or Alizarin red S, can confirm the presence of calcium.

Aetiology and Risk Factors

While hyperadrenocorticism (both pituitary-dependent and adrenal-dependent) is the most common cause of calcinosis cutis in dogs, other aetiologies exist. Understanding the underlying cause is critical for effective treatment.

Primary Aetiology: Hyperadrenocorticism (Cushing's Syndrome)

Approximately 80% to 90% of cases of calcinosis cutis in dogs are associated with hyperadrenocorticism (HAC). This can be either:

• Pituitary-Dependent Hyperadrenocorticism (PDH): Caused by a micro- or macroadenoma of the pituitary gland, leading to excessive secretion of adrenocorticotropic hormone (ACTH), which stimulates the adrenal glands to produce excess cortisol. This is the most common form, accounting for 80-85% of spontaneous cases.
• Adrenal-Dependent Hyperadrenocorticism (ADH): Caused by a functional adenoma or carcinoma of the adrenal cortex, leading to autonomous cortisol secretion.
• Iatrogenic Hyperadrenocorticism: Caused by excessive or prolonged administration of exogenous glucocorticoids (e.g., prednisolone, dexamethasone, topical steroids).

The link between HAC and calcinosis cutis is so strong that the presence of calcinosis cutis is considered a highly specific, albeit not sensitive, marker for the disease. According to the Merck Veterinary Manual, calcinosis cutis is one of the more characteristic dermatologic manifestations of Cushing's syndrome in dogs.

Other, Less Common Aetiologies

• Chronic Renal Failure: In cases of secondary hyperparathyroidism due to chronic kidney disease (CKD), the calcium-phosphorus product can become elevated, leading to metastatic calcification, including in the skin. This is less common than dystrophic calcification but is well documented.
• Diabetes Mellitus: Uncontrolled diabetes can lead to alterations in calcium and phosphorus metabolism, potentially contributing to calcification.
• Dietary Imbalances: Although rare, excessive dietary calcium or vitamin D (e.g., from rodenticide poisoning or certain supplements) can cause hypercalcaemia and subsequent metastatic calcification.
• Idiopathic Calcinosis Cutis: In very rare cases, no underlying cause can be identified.
• Local Trauma or Inflammation: Dystrophic calcification can occur at sites of chronic irritation, injection sites, or foreign body reactions, but this is less common than the generalized form seen with HAC.

Breed and Signalment

While any dog can develop calcinosis cutis, certain breeds are predisposed to hyperadrenocorticism and, by extension, this condition. These include:

• Poodle (Miniature and Toy)
• Dachshund
• Boston Terrier
• Boxer
• Beagle
• Yorkshire Terrier
• German Shepherd Dog

The condition is typically seen in middle-aged to older dogs (mean age 6-10 years), reflecting the age distribution of Cushing's disease. There is no strong sex predilection, although some studies suggest a slight female predominance for PDH.

Clinical Presentation and Symptoms

The clinical signs of calcinosis cutis are highly variable, ranging from subtle changes to severe, debilitating skin disease. The lesions are often progressive if the underlying endocrinopathy is not addressed.

Primary Skin Lesions

The classic presentation involves firm, palpable, plaque-like or nodular lesions within the skin. These can be described as:

• Papules and Nodules: Small to medium-sized, firm, raised lesions.
• Plaques: Larger, flat-topped, indurated areas of skin thickening.
• Crusting and Scaling: The overlying epidermis often becomes dry, scaly, and hyperkeratotic.
• Ulceration and Erosion: As the lesions progress, the skin can become fragile and ulcerate, leading to secondary bacterial infections.
• Erythema: The affected skin is often red and inflamed.
• Alopecia: Hair loss is common over the lesions.

A pathognomonic feature of calcinosis cutis in dogs is the presence of white, chalky, gritty material that can be expressed from the lesions. This material is the calcium salt deposit. Owners may report seeing white "specks" or "grains" in the fur or on the skin.

Anatomical Distribution

The lesions of calcinosis cutis have a characteristic distribution, which can aid in diagnosis. Common sites include:

• Dorsum of the Neck and Back (Interscapular Region): This is the most common site, often described as a "calcium collar" or "shield."
• Axillae and Groin (Inguinal Region): The flexural areas are frequently affected.
• Medial Thighs and Abdomen: The ventral abdomen and inner thighs are common sites.
• Head and Face: Lesions can occur on the bridge of the nose, around the eyes, and on the pinnae (ear flaps).
• Pressure Points: Over the elbows, hocks, and other bony prominences.

Associated Systemic Signs

Since calcinosis cutis is usually a manifestation of hyperadrenocorticism, affected dogs will often show other classic signs of Cushing's syndrome. These include:

• Polyuria and Polydipsia (PU/PD): Increased urination and thirst.
• Polyphagia: Increased appetite.
• Abdominal Distension (Pot-Bellied Appearance): Due to muscle weakness and fat redistribution.
• Muscle Weakness and Lethargy: Especially in the hind limbs.
• Hepatomegaly: Enlarged liver.
• Recurrent Urinary Tract Infections (UTIs): Due to immunosuppression.
• Calcinosis Circumscripta: In some cases, concurrent discrete nodular calcifications may be present.
• Dermatologic Signs: Thin, fragile skin (skin that tears easily), poor wound healing, and comedones (blackheads) on the ventral abdomen.

Secondary Complications

The most common complication of calcinosis cutis is secondary bacterial pyoderma. The damaged, ulcerated skin is highly susceptible to infection, most commonly with Staphylococcus pseudintermedius. This can lead to pruritus (itching), pain, malodour, and systemic illness if left untreated. In severe cases, deep pyoderma or cellulitis can develop.

Diagnosis: A Step-by-Step Approach

Diagnosing calcinosis cutis involves a combination of physical examination, cytology, histopathology, and diagnostic testing for the underlying cause. A systematic approach is essential.

Step 1: Clinical Suspicion

The diagnosis often begins with a high index of suspicion. The presence of firm, plaque-like lesions in the classic distribution (dorsal neck, axillae, groin) in a middle-aged to older dog, especially a predisposed breed, should immediately raise suspicion for calcinosis cutis. The presence of concurrent signs of Cushing's disease (PU/PD, polyphagia, pot-bellied appearance) further strengthens the suspicion.

Step 2: Cytology (Fine Needle Aspiration)

A fine needle aspirate (FNA) of a lesion can be a rapid, non-invasive, and highly informative first step.

• Procedure: A small-gauge needle (22-25G) is inserted into the lesion, and material is aspirated. The sample is then expelled onto a glass slide, air-dried, and stained (e.g., Diff-Quik).
• Findings: Cytology will typically show an amorphous, basophilic, granular background material that is the calcium deposit. Inflammatory cells, particularly macrophages and multinucleated giant cells (foreign body reaction), are often present. The absence of infectious organisms (e.g., bacteria, fungal elements) helps rule out other causes of nodular dermatitis.

Step 3: Histopathology (Skin Biopsy)

A full-thickness skin biopsy is the gold standard for definitive diagnosis. It is essential for confirming the nature of the calcification and ruling out other conditions.

• Procedure: Under local or general anaesthesia, a 6-8 mm punch biopsy is taken from the centre of a representative lesion. The sample is placed in 10% neutral buffered formalin and submitted to a veterinary pathology laboratory.
• Findings: Histopathology will confirm the presence of basophilic, granular calcium deposits in the dermis, often with a surrounding granulomatous inflammatory reaction. Special stains (von Kossa, Alizarin red) can confirm the mineral nature.

Step 4: Diagnostic Testing for Hyperadrenocorticism

Given the strong association, once calcinosis cutis is confirmed, a thorough workup for Cushing's syndrome is mandatory. The diagnostic approach for HAC is well established and includes:

• Complete Blood Count (CBC) and Serum Biochemistry Profile: These are supportive but not diagnostic. Classic findings in HAC include:
  • CBC: Stress leukogram (neutrophilia, lymphopenia, eosinopenia), thrombocytosis.
  • Biochemistry: Elevated alkaline phosphatase (ALP, often steroid-induced isoenzyme), alanine aminotransferase (ALT), cholesterol, and glucose. Low blood urea nitrogen (BUN).
• Urinalysis: Low urine specific gravity (<1.020) due to PU/PD. Concurrent urinary tract infection is common.
• ACTH Stimulation Test: This is the most commonly used screening test. Blood is drawn before and 1-2 hours after administration of synthetic ACTH (cosyntropin). An exaggerated cortisol response is diagnostic for HAC. This test is also used to monitor response to treatment (e.g., trilostane).
• Low-Dose Dexamethasone Suppression Test (LDDST): This is the most sensitive screening test for PDH. Blood is drawn before and 4 and 8 hours after a low dose of dexamethasone. In normal dogs, cortisol is suppressed. In PDH, there is either no suppression or a characteristic "escape" pattern. In ADH, there is no suppression.
• Abdominal Ultrasound: This is used to differentiate PDH from ADH. In PDH, both adrenal glands are typically symmetrically enlarged. In ADH, one adrenal gland is enlarged (with a mass), while the contralateral gland is often atrophied.
• Endogenous ACTH Measurement: This can help differentiate PDH (high ACTH) from ADH (low ACTH).

Step 5: Ruling Out Other Causes

If HAC is ruled out, other aetiologies must be considered:

• Serum Calcium and Phosphorus Levels: To screen for hypercalcaemia and hyperphosphataemia (e.g., due to renal failure, hyperparathyroidism, or vitamin D toxicity).
• Renal Function Tests: BUN, creatinine, and urine protein:creatinine ratio to assess for chronic kidney disease.
• Parathyroid Hormone (PTH) Level: To evaluate for hyperparathyroidism.

Differential Diagnoses

Several other skin conditions can mimic the appearance of calcinosis cutis. A definitive diagnosis via biopsy is crucial. Key differentials include:

• Calcinosis Circumscripta: Discrete, nodular, tumour-like deposits, often over bony prominences. Not associated with HAC.
• Neoplasia: Cutaneous lymphoma, mast cell tumour, histiocytoma, or other skin tumours.
• Deep Pyoderma or Furunculosis: Severe bacterial infections can cause nodular, ulcerated lesions.
• Demodicosis: Mite infestation can cause severe, crusting dermatitis.
• Dermatophytosis (Ringworm): Fungal infection can cause circular, crusting lesions.
• Sterile Nodular Panniculitis: Inflammation of the subcutaneous fat.
• Xanthomas: Lipid deposits in the skin, usually associated with hyperlipidaemia.

Treatment and Management

The treatment of calcinosis cutis is primarily directed at the underlying cause. The skin lesions themselves are a symptom, and they will typically regress once the primary disease is controlled. However, symptomatic and supportive care is often necessary to manage pain, infection, and discomfort.

1. Treating the Underlying Hyperadrenocorticism

This is the cornerstone of therapy. The choice of treatment depends on the type of HAC.

• Medical Management for PDH:

  • Trilostane (Vetoryl): This is the current drug of choice for PDH. It is a competitive inhibitor of 3β-hydroxysteroid dehydrogenase, blocking cortisol synthesis. Dosage is typically 1-3 mg/kg orally once daily, with food. Monitoring is essential via ACTH stimulation tests 4-6 hours after the dose, aiming for a post-ACTH cortisol of 1.5-5.5 µg/dL (41-150 nmol/L). Side effects include vomiting, diarrhoea, lethargy, and, rarely, hypoadrenocorticism (Addisonian crisis).
  • Mitotane (Lysodren): An older drug that causes selective necrosis of the zona fasciculata and zona reticularis of the adrenal cortex. It is effective but requires careful loading and maintenance phases with close monitoring. Side effects include anorexia, vomiting, diarrhoea, and ataxia. It is less commonly used now due to the safety profile of trilostane.
  • Selegiline (Anipryl): Used for uncomplicated PDH, but its efficacy is less predictable than trilostane or mitotane. It works by increasing dopamine levels, which can reduce ACTH secretion.

• Surgical Management for ADH:

  • Adrenalectomy: Surgical removal of the affected adrenal gland is the treatment of choice for adrenal tumours. This is a major surgery requiring a skilled surgeon and intensive post-operative care. It offers a potential cure if the tumour is benign and completely excised.
  • Medical Management for ADH: If surgery is not possible (e.g., due to metastasis, poor surgical candidate), medical management with trilostane or mitotane can be used to control cortisol excess, though it is palliative.

• Management of Iatrogenic HAC:

  • Tapering and Discontinuation of Glucocorticoids: The underlying cause is the exogenous steroid. The drug must be slowly tapered over weeks to months to allow the adrenal glands to recover. This should be done under veterinary supervision.

2. Symptomatic Treatment of Skin Lesions

While waiting for the HAC treatment to take effect (which can take weeks to months), the skin lesions require active management.

• Topical Therapy:

  • Emollients and Moisturizers: To reduce dryness and scaling. Products containing ceramides, fatty acids, or oatmeal can be helpful.
  • Antibacterial/Antifungal Shampoos: Chlorhexidine or miconazole shampoos can help control secondary pyoderma.
  • Topical Steroids: Low-potency topical steroids (e.g., hydrocortisone) can reduce local inflammation but must be used cautiously due to the risk of systemic absorption in a dog with HAC.
  • Dimethyl Sulfoxide (DMSO): DMSO is a topical anti-inflammatory and free radical scavenger that has been used anecdotally to help dissolve calcium deposits. It is applied topically as a gel (usually 50-90% solution) to the lesions. It can be irritating and has a strong odour. Its use is controversial and not a primary therapy.
  • Topical Tacrolimus or Cyclosporine: These calcineurin inhibitors have been used in some cases to reduce inflammation and possibly modulate calcium deposition, but evidence is limited.

• Systemic Therapy:

  • Systemic Antibiotics: If a secondary bacterial pyoderma is present, a prolonged course of culture-guided antibiotics is necessary. Cephalexin, amoxicillin-clavulanate, or clindamycin are common choices. Treatment should continue for at least 2-4 weeks beyond clinical resolution.
  • Pain Management: Calcinosis cutis can be painful. Non-steroidal anti-inflammatory drugs (NSAIDs) are generally contraindicated in dogs with HAC due to the risk of gastrointestinal ulceration and renal compromise. Gabapentin or amantadine may be used for neuropathic pain.
  • Dietary Modification: Some clinicians recommend a low-calcium, low-phosphorus diet to reduce the substrate for calcification, though evidence for this is weak. A high-quality, balanced diet is always recommended.

• Surgical Debridement:

  • In severe, localized cases where lesions are large, necrotic, or causing significant pain or infection, surgical excision may be considered. However, this is rarely a first-line treatment. The skin of dogs with HAC is fragile and heals poorly, so surgery carries a high risk of dehiscence (wound breakdown) and infection. It is typically reserved for cases that are refractory to medical management.

3. Monitoring and Follow-Up

• For HAC: Dogs on trilostane or mitotane require regular monitoring with ACTH stimulation tests (every 1-3 months initially, then every 6-12 months once stable). Clinical signs (PU/PD, appetite, energy level) should be monitored closely.
• For Skin Lesions: The skin lesions should be photographed and measured at each recheck. They typically begin to regress within 4-8 weeks of effective HAC treatment. Complete resolution can take 3-6 months or longer. Owners should be warned that the lesions may appear to worsen before they improve, as the body resorbs the calcium deposits.

Prognosis

The prognosis for a dog with calcinosis cutis is directly tied to the prognosis for the underlying cause.

• For PDH: With appropriate medical management (trilostane), the prognosis is generally good to excellent. Most dogs live for years with a good quality of life. The skin lesions will typically resolve completely, although some scarring or alopecia may remain.
• For ADH: The prognosis depends on the nature of the adrenal tumour. If it is a benign adenoma that is surgically removed, the prognosis is excellent. If it is a malignant carcinoma or if metastasis is present, the prognosis is guarded to poor. Medical management can provide palliation for months to years.
• For Iatrogenic HAC: The prognosis is excellent once the exogenous steroids are withdrawn, provided the underlying condition for which they were prescribed can be managed without them.
• For Other Causes: The prognosis is variable. For renal failure-related calcinosis, the prognosis is poor due to the progressive nature of CKD. For idiopathic cases, the prognosis is guarded.

Prevention

Prevention of calcinosis cutis is largely about preventing the underlying causes.

• Judicious Use of Glucocorticoids: Avoid unnecessary or prolonged use of systemic or topical steroids. Use the lowest effective dose for the shortest duration possible. Taper off steroids slowly when discontinuing.
• Early Diagnosis of Cushing's Disease: Regular veterinary check-ups, especially for senior dogs of predisposed breeds, can help detect HAC early, before severe skin changes develop. Owners should be educated about the early signs of Cushing's (PU/PD, polyphagia, pot-bellied appearance).
• Diet and Nutrition: Feed a balanced, age-appropriate diet. Avoid calcium or vitamin D supplementation without veterinary advice.
• Monitoring for CKD: Regular bloodwork and urinalysis for senior dogs can help detect chronic kidney disease early.

Regional Considerations

United States and Canada

In North America, the diagnostic approach and treatment protocols for HAC and calcinosis cutis are well standardized. The AAHA (American Animal Hospital Association) and AVMA (American Veterinary Medical Association) provide guidelines for endocrine testing. Trilostane (Vetoryl) is the most commonly used medical therapy. The availability of advanced imaging (CT, MRI) and referral to internal medicine specialists is widespread in major urban centres.

Europe

In Europe, the Federation of Veterinarians of Europe (FVE) and the European Medicines Agency (EMA) regulate veterinary pharmaceuticals. Trilostane is also the first-line medical treatment. The diagnostic approach is similar, though access to certain diagnostic tests (e.g., endogenous ACTH) may vary by country. In the UK, the British Small Animal Veterinary Association (BSAVA) provides comprehensive guidelines.

Australia

In Australia, the Australian Veterinary Association (AVA) provides clinical guidelines. The approach to diagnosing and managing HAC is consistent with international standards. The Department of Agriculture, Fisheries and Forestry (DAFF) regulates veterinary medicines. Trilostane is available and widely used. Given the unique tick species in Australia (e.g., paralysis tick, Ixodes holocyclus), any dog with skin lesions should be carefully evaluated for tick paralysis, though this is not directly related to calcinosis cutis.

Frequently Asked Questions (FAQs)

Q: Is calcinosis cutis painful for my dog?

A: Yes, it can be. The lesions are often firm, inflamed, and can become ulcerated and infected. This can cause significant discomfort, pruritus (itching), and pain. Pain management, often with gabapentin, may be necessary.

Q: Can calcinosis cutis be cured?

A: The skin lesions themselves can resolve, but the condition is a symptom of an underlying disease. If the underlying hyperadrenocorticism is successfully treated (medically or surgically), the skin lesions will typically regress completely over several months. If the underlying cause cannot be controlled, the lesions may persist or worsen.

Q: How long does it take for the skin lesions to go away?

A: Improvement is usually seen within 4-8 weeks of starting effective treatment for Cushing's disease. Complete resolution of the lesions can take 3-6 months or longer. In some cases, residual scarring or alopecia may remain.

Q: Is calcinosis cutis contagious to other pets or humans?

A: No, it is not contagious. It is a metabolic/endocrine disorder, not an infectious disease.

Q: What is the difference between calcinosis cutis and calcinosis circumscripta?

A: Calcinosis cutis is a diffuse, often widespread deposition of calcium within the skin, strongly associated with Cushing's disease. Calcinosis circumscripta is a discrete, nodular, tumour-like deposit of calcium, often found over bony prominences (e.g., elbows, hocks). It is not associated with Cushing's disease and is often idiopathic or post-traumatic.

Q: Can diet help treat calcinosis cutis?

A: While a balanced diet is essential for overall health, there is no specific "calcinosis cutis diet." Some clinicians recommend a low-calcium, low-phosphorus diet, but the evidence is weak. The primary treatment is addressing the underlying endocrine disease.

Q: My dog has a small, white, gritty spot on his back. Should I be worried?

A: It could be a small lesion of calcinosis cutis, or it could be something else like a sebaceous cyst or a foreign body. It is best to have it examined by your veterinarian. If it is calcinosis cutis, early diagnosis and treatment of the underlying cause can prevent progression.

Conclusion

Calcinosis cutis in dogs is a striking and clinically important dermatologic manifestation of a systemic endocrine disorder, most commonly hyperadrenocorticism. For the veterinary professional, it serves as a critical diagnostic clue that should prompt a thorough investigation for Cushing's syndrome. For the pet owner, it can be a distressing and painful condition for their beloved companion.

The key to successful management lies in a systematic diagnostic approach: clinical suspicion, cytology, histopathology, and endocrine testing. Treatment is twofold: definitive management of the underlying HAC (with trilostane, mitotane, or surgery) and symptomatic care for the skin lesions (including antibiotics for secondary infection, pain management, and topical therapies). With appropriate and timely intervention, the prognosis is generally good, and the skin lesions can resolve completely, restoring the dog's comfort and quality of life.

This comprehensive reference guide underscores the importance of viewing calcinosis cutis not as a primary skin disease, but as a visible marker of a deeper, treatable systemic illness. By understanding its pathophysiology, recognizing its clinical presentation, and implementing evidence-based treatment, veterinarians and pet owners can work together to achieve the best possible outcome for the affected dog.

References

1. Feldman, E. C., & Nelson, R. W. (2014). Canine and Feline Endocrinology (4th ed.). Saunders.
2. Miller, W. H., Griffin, C. E., & Campbell, K. L. (2013). Small Animal Dermatology (7th ed.). Saunders.
3. Merck Veterinary Manual. (2023). Hyperadrenocorticism in Dogs. Retrieved from merckvetmanual.com.
4. American Animal Hospital Association (AAHA). (2023). AAHA Canine Vaccination Guidelines.
5. Behrend, E. N., Kooistra, H. S., Nelson, R. W., Reusch, C. E., & Scott-Moncrieff, J. C. (2013). Diagnosis of spontaneous canine hyperadrenocorticism: 2012 ACVIM consensus statement (small animal). Journal of Veterinary Internal Medicine, 27(6), 1292-1304.
6. Scott-Moncrieff, J. C. (2015). Clinical Signs and Concurrent Diseases of Hyperadrenocorticism in Dogs. Veterinary Clinics of North America: Small Animal Practice, 45(2), 243-256.
7. Guaguère, E., & Prélaud, P. (2011). A Practical Guide to Canine Dermatology. Merial.
8. Gross, T. L., Ihrke, P. J., Walder, E. J., & Affolter, V. K. (2005). Skin Diseases of the Dog and Cat: Clinical and Histopathologic Diagnosis (2nd ed.). Blackwell Publishing.
9. Australian Veterinary Association (AVA). (2023). Guidelines for the Diagnosis and Management of Canine Hyperadrenocorticism.
10. Federation of Veterinarians of Europe (FVE). (2023). Position on the Use of Corticosteroids in Veterinary Medicine.
11. Cornell University College of Veterinary Medicine. (2023). Cushing's Disease in Dogs. Retrieved from vet.cornell.edu.
12. VCA Animal Hospitals. (2023). Calcinosis Cutis in Dogs. Retrieved from vcahospitals.com.
13. DVM360. (2023). Dermatologic Manifestations of Canine Cushing's Disease.
14. Kintzer, P. P., & Peterson, M. E. (1991). Mitotane (o,p'-DDD) treatment of 200 dogs with pituitary-dependent hyperadrenocorticism. Journal of Veterinary Internal Medicine, 5(3), 182-190.
15. Neiger, R., Ramsey, I., O'Connor, J., Hurley, K. J., & Mooney, C. T. (2002). Trilostane treatment of 78 dogs with pituitary-dependent hyperadrenocorticism. Veterinary Record, 150(26), 799-804.